125256-00-0
中文名稱
FATOSTATIN A
英文名稱
Fatostatin A
CAS
125256-00-0
分子式
C18H18N2S
分子量
294.41
MOL 文件
125256-00-0.mol
更新日期
2024/11/18 09:41:57
125256-00-0 結(jié)構(gòu)式
基本信息
中文別名
脂肪抑制素 英文別名
125B11Pyridine, 4-[4-(4-methylphenyl)-2-thiazolyl]-2-propyl-
4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole
物理化學(xué)性質(zhì)
沸點(diǎn)474.3±55.0 °C(Predicted)
密度1.125±0.06 g/cm3(Predicted)
儲(chǔ)存條件Inert atmosphere,2-8°C
溶解度溶于 DMSO（高達(dá) 25 mg/ml）。
酸度系數(shù)(pKa)3.46±0.10(Predicted)
形態(tài)固體
顏色黃色
穩(wěn)定性DMSO中的溶液可在-20°下穩(wěn)定儲(chǔ)存3個(gè)月。
FATOSTATIN A價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | S9785 | FATOSTATIN A Fatostatin | 125256-00-0 | 5mg | 795.2元 |
| 2024/11/08 | S9785 | Fatostatin | 125256-00-0 | 10mM (1mL in DMSO) | 958.23元 |
| 2024/11/08 | S9785 | FATOSTATIN A Fatostatin | 125256-00-0 | 25mg | 2375.39元 |
常見問題列表
生物活性
Fatostatin (125B11) 是一種diarylthiazole的衍生物，是 Sterol regulatory element binding proteins (SREBPs) 活化的特異性抑制劑。Fatostatin 可結(jié)合SCAP (SREBP cleavage-activating protein)，并抑制SREBP的ER-Golgi易位。Fatostatin 可抑制癌細(xì)胞生長(zhǎng)并增強(qiáng)癌細(xì)胞的凋亡。靶點(diǎn)
| Target | Value |
|
SREBP
() |
體外研究
Fatostatin (125B11) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC
50
=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells.
Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC
50
of 2.5 and 10 μM in mammalian cells.
Cell Proliferation Assay
| Cell Line: | DU-145 cells |
| Concentration: | 0.1, 1 μM |
| Incubation Time: | 3 days |
| Result: | Impaired the IGF1-induced growth at an IC 50 of 0.1 μM. |
體內(nèi)研究
Fatostatin (125B11) (30 mg/kg; 150 μL; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice.
| Animal Model: | Four-to-five-week-old homozygous male obese ( ob/ob ) mice (C57BL/6J) |
| Dosage: | 30 mg/kg; 150 μL |
| Administration: | i.p. injection; daily for 28 days |
| Result: | Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. |